

PRESS RELEASE

Biofortis and Teranga strengthen their service offerings with the acquisition of NEOVIX group

Nantes France, March 6, 2025 – The Biofortis group, in association with the TERANGA group, has finalised the acquisition of the regulatory and quality, audit, training and cosmetic formulation activities of the companies in the Neovix group (AR2i, Cosmetic Office, White Tillet and SCM cosmetics and Qualilab).

At the same time as this acquisition, CEBIPHAR, a member of the TERANGA group, acquired the analytical activities of the AR2i laboratory.

Convinced of the strong potential for synergy associated with the merger of our groups, this acquisition will accelerate the growth of our activities in connection with the development of drugs, medical devices, food supplements and cosmetic products, in order to provide the best possible support for our customers' research and development projects.

With CEBIPHAR (a GMP pharmaceutical establishment) continuing to operate as a control laboratory, we can guarantee our industrial customers continuity of analytical services within the same regulatory framework. With sites in Fondettes (Indre et Loire), Bellegarde (Loiret) and Toulouse, the TERANGA group is strengthening its presence and its range of services for industrial customers.

Benoit Fouchaq - CEO of Biofortis: "I am delighted to share this new step with TERANGA. The shared values of quality, scientific excellence and operational excellence shared by our groups will strengthen our position in markets related to health and well-being. This acquisition will enable us to provide our customers with the best possible support, from the regulatory positioning of products to the preparation of marketing authorization dossiers in a changing regulatory environment. Our expertise

in clinical research, data management and statistics, combined with our analytical, quality control and audit activities, will accelerate the time-to-market for products under development, while simplifying project management for our customers and partners."

Eric Petat – CEO of TERANGA and CEBIPHAR: "Thanks to this strategy, the TERANGA Group, which owns CEBIPHAR as well as ACM PHARMA (microbiology) and UPS Consultants (training, consultancy and technical assistance), is looking to the future to strengthen the services that our two groups offer their partners. I'm delighted to be joining forces with the BIOFORTIS group, with whom we share the same human values of proximity and service to our customers, in complete independence."

About Biofortis group

The Biofortis group operates as CROs or Contract Research Organisations specialising in conducting research projects on behalf of clients in the agri-food, pharmaceutical and cosmetics industries. With over 20 years' experience, companies are recognised in their respective markets and work with clients ranging from local players to multinationals.

Activities supported by the group include the conduct of clinical trials, the collection and analysis of biological samples, data management and analysis, and regulatory support. More recently, the establishment of capabilities for the collection of human samples for therapeutic purposes has enabled the development of new therapeutic solutions based on the restoration of microbiomes in the treatment of resistant bacterial infections, infertility and the fight against cancer.

The group has its headquarters and main activities in Nantes, Paris and Berlin, and is able to provide services in Europe and the rest of the world.

For further information, please visit our website: <https://www.biofortis.fr/>

About Teranga group

The TERANGA group is an independent family holding created in 2008. The group currently runs 4 companies: ACM PHARMA, CEBIPHAR, UPS CONSULTANTS and ACD SWISS. TERANGA combines the synergy of a group with the flexibility and agility of companies on a human scale.

Our companies meet all the needs of our partners in the pharmaceutical, cosmetics and medical device industries in terms of analytical and microbiological control, consultancy, training and technical assistance, thanks to personalised local services. With a team of more than 220 employees, the group shares common values in order to establish reliable, long-term partnerships with its customers, offering them technical and regulatory solutions tailored to their needs and helping them to make their projects a success.

For further information, please visit our website: <https://terangagroupe.com/>



CONTACTS – Media Relations

Biofortis

Clémence Chesneau,

Sales & Communication Officer

biofortis-contact@biofortis.fr

+33(0)2 40 20 57 99

TERANGA group

Eric PETAT

Président

eric.petat@terangagroupe.com

33(0) 2 38 90 41 01